Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81
Document › Details

Metrion Biosciences Ltd.. (9/17/18). "Press Release: Metrion Biosciences Makes Senior Appointments to Strengthen Its Drug Discovery Leadership tTeam". Cambridge.

Organisations Organisation Metrion Biosciences Ltd.
  Organisation 2 Ario Pharma Ltd.
Products Product drug discovery
  Product 2 medicinal chemistry
Persons Person Odgaard, Katie (Zyme Communications 201108 Senior Account Manager before College Hill Life Sciences)
  Person 2 Lightfoot, Andrew (Peptinnovate Ltd 201506 CEO)

Dr Edward Stevens appointed as Head of Drug Discovery, and Dr Andrew Lightfoot as Head of Medicinal Chemistry and Discovery Funding

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has made two senior appointments to its management team. Dr Edward Stevens joins the Company as Head of Drug Discovery, and Dr Andrew Lightfoot as Head of Medicinal Chemistry and Discovery Funding.

These appointments follow the expansion of Metrion’s internal drug discovery programme, driven by funding from Innovate UK, to support research into potassium ion channel inhibitors. The internal proprietary programme will now be led by Dr Stevens and Dr Lightfoot, and is based on a portfolio of more than 2,000 novel small molecule inhibitors of potassium ion channels acquired by Metrion in January 2018. The Company is evaluating the lead compounds as potential orally active drugs for treatment of auto-immune disorders such as multiple sclerosis, psoriasis, ulcerative colitis, and rheumatoid arthritis.

Dr Edward Stevens joins Metrion from Ario Pharma, where he was Chief Scientific Officer. Prior to this, he held various roles at Pfizer Neusentis and Pfizer Sandwich, including Head of Electrophysiology a member of the Pain Research Unit Leadership Team, and led several ion channel discovery programmes. Dr Stevens was also previously Chief Operating Officer for NeuroSolutions, a Warwick University spin-out company, and Head of the Ion Channel Group at Cambridge Drug Discovery/BioFocus (now part of Charles River).

Dr Andrew Lightfoot is currently Chief Executive Officer at Procarta Biosystems and in his new role at Metrion will continue in this position. He was also previously Chief Executive Officer and founder of Peptinnovate, a UK-based, clinical stage biopharmaceutical company, Executive Director of Swedish medtech CytaCoat AB, and Chief Executive Officer of Helperby Therapeutics. Dr Lightfoot has also held various research project leadership positions at GSK, including Associate Director, Neurosciences, as a member of the Discovery Performance Unit Leadership Team, and led a drug discovery programme to candidate selection at GSK in Verona, Italy.

Dr Keith McCullagh, Chairman, Metrion Biosciences, said: “Both Eddy and Andrew have already supported Metrion in developing a number of internal drug discovery projects this year, and also in securing funding for in-house research. I am delighted to welcome them to formal positions at the Company, where they will play an important role in the further advancement of our proprietary ion channel research programmes, with the aim of securing significant future research collaborations with pharma partners.”

- Ends -

Media Contacts

For Metrion

Katie Odgaard
Zyme Communications
Tel: +44 (0)7787 502 947

Keith McCullagh PhD
Chairman, Metrion Biosciences

About Metrion Biosciences

Metrion Biosciences is a specialist ion-channel contract research organisation and drug discovery business. The Company provides customers with access to a range of high quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences’ specialist ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimisation. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages. For more information, see:

Record changed: 2018-09-20


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Metrion Biosciences Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top